Novavax (NVAX) Stock: Is A Buyout Coming?

What We’re Seeing From The Stock 

As the flu epidemic gets worse, Novavax investors continue to get more and more excited. After all, their NanoFlu product could prove to be a massive financial for the company and all involved. With the takeover speculation and excitement surrounding NanoFlu, it’s no surprise to see that the stock is making a run for the top. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (1:33), NVAX is trading at $2.07 per share after a gain of $0.19 per share or 10.11% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on NVAX. In particular, we’re interested in following the data surrounding NanoFlu and any insinuation of a takeover in the works. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Add Comment